November 4, 2024 01:46 PM EST
Pharma

BioN­Tech eas­es 2024 rev­enue out­look de­spite hefty Covid vac­cine third-quar­ter sales

Ayisha Sharma

News Reporter

De­spite strong third-quar­ter rev­enues, BioN­Tech has soft­ened its 2024 sales guid­ance in light of changes to Covid-19 vac­cine up­take, pric­ing and sea­son­al vari­a­tions.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times